Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
2014 ◽
Vol 1
(3)
◽
pp. e112-e119
◽
2014 ◽
Vol 15
(8)
◽
pp. 874-885
◽
2017 ◽
Vol 4
(9)
◽
pp. e431-e442
◽